Physician profile
Ahmad Y Alshash
NPI 1881607786
$872.43
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $807 · 2020: $53.85 · 2021: $11.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $223.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $138.57 | 2019-2020 | |
| Pharming Healthcare, INC. | $119.61 | 2019 | |
| Glaxosmithkline, LLC. | $72.50 | 2019-2020 | |
| Jubilant Hollisterstier LLC | $56.51 | 2019 | |
| Genzyme Corporation | $45.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $38.80 | 2019 | |
| Circassia INC. | $25.37 | 2019-2020 | |
| Grifols USA, LLC | $25.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.67 | 2019 | |
| Kaleo, INC. | $13.18 | 2019 | |
| Phadia US INC. | $12.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.78 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $11.78 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmad Alshash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.